Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Reported 84 thousand tests in the third quarter, up 12% compared to the second quarter Achieved a preeclampsia test analytical verification milestone Management will host conference call and webcast...
-
Dublin, Nov. 09, 2020 (GLOBE NEWSWIRE) -- The "North America Microtome Market to 2027 - Country Analysis and Forecasts by Product (Microtome Instruments, Microtome Accessories); Technology (Manual...
-
Dublin, Nov. 06, 2020 (GLOBE NEWSWIRE) -- The "Global Dental Diagnostics & Surgical Equipment Market (By Segment and Region), Impact of COVID-19, Company Analysis - Forecast to 2026" report has...
-
SAN DIEGO, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
-
Dublin, Nov. 05, 2020 (GLOBE NEWSWIRE) -- The "North America Breast Cancer Screening Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Test Type; End User, and Countries" report has...
-
Dublin, Nov. 05, 2020 (GLOBE NEWSWIRE) -- The "Global COVID-19 Diagnostic Testing Market: Focus on Product Type, Sample Type, Technology, End User, Country Data (30 Countries), and Competitive...
-
SAN DIEGO, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
-
Portland, OR, Nov. 02, 2020 (GLOBE NEWSWIRE) -- As per the report published by Allied Market Research, the global Covid-19 diagnostics market generated $73.19 million in the first quarter of 2020,...
-
Announces Expansion of its COVID-19 Testing Offering Provides Preliminary Third Quarter 2020 Financial Update SAN DIEGO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a...
-
SAN DIEGO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...